NCT02651194View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

January 31, 2017

Conditions
Chronic Hepatitis C Virus (HCV) Infection
Interventions
DRUG

ABT-493/ABT-530

Tablet; ABT-493 coformulated with ABT-530

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY